In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, an analyst ...

Atai Life Sciences N.V. reported positive top-line phase 2a results of BPL-003 in treating Alcohol Use Disorder patients.

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on ATAI Life Sciences (ATAI – Research Report). The associated ...

Atai Life Sciences (NASDAQ:ATAI) reported positive topline results from a Phase 2a study of the psychedelic drug BPL-003 in the treatment of patients with moderate to severe alcohol use disorder, or ...

ATAI Life Sciences N.V. (NASDAQ:ATAI), a pharmaceutical company specializing in the development of treatments for mental health conditions with a market capitalization of $263 million, announced the ...

Beckley Psytech has announced that it has received substantial strategic investment from Germany-based atai Life Sciences, totalling $50 million, to accelerate the clinical development of short ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

(RTTNews) - Biopharmaceutical company atai Life Sciences N.V. (ATAI) announced Friday key leadership appointments to advance its goal of delivering novel mental health therapeutics. Srinivas Rao ...

Sustainalytics’ Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company’s operations. Controversies ...